Vitamin K2 Supplementation and Arterial Stiffness in the Renal Transplant Population (The KING Trial)

Lebanese American University60 enrolled

Overview

This study is a single arm, single center clinical trial that aims to evaluate the effect of 8 weeks of vitamin K2 replacement (360 mcg/day) on the progression of arterial stiffness in stable renal transplant patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Arterial Stiffness Vitamin K2 Deficiency

Interventions

Vitamin K2 (MK7)DIETARY_SUPPLEMENT

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Functional renal graft * Stable renal function for at least 3 months prior to enrollment Exclusion Criteria: * History of thrombotic events * Diagnosed coagulopathy * Cardiovascular event in the past month prior to enrollment * Current or planned pregnancy * Lactation * Soy allergy * Concomitant or recent (past 6 months) use of supplements that contain vitamin K * Warfarin treatment * Known intestinal malabsorption or hypomotility syndromes

Locations (1)

Lebanese American University Medical Center - Rizk Hospital

El Achrafiyé, Beyrouth, Lebanon

Outcomes

Primary Outcomes

Reduction From Baseline in Carotid-femoral Pulse Wave Velocity at 8 Weeks

Time frame: 8 weeks

Secondary Outcomes

Change From Baseline in Central Pressure by Ambulatory Hemodynamic Measurement (Mobil-O-Graph) at 8 Weeks

Time frame: 8 weeks

Change From Baseline in Augmentation Index by Ambulatory Hemodynamic Measurement (Mobil-O-Graph) at 8 Weeks

Time frame: 8 weeks

Change From Baseline in Blood Concentration of Dephosphorylated-uncarboxylated Matrix Gla Protein (Dp-ucMGP) at 8 Weeks

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.